Skip to main content

troriluzole

troriluzole: 3 clinical trials tracked.

troriluzole evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about troriluzole, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trials (3)

A Randomized, Double-Blind, Placebo- Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder

NCT04693351·Phase 3·WST
Completed

Primary endpoint: Change From Baseline in the Y-BOCS Total Score in the Baseline Y-BOCS ≥24 Stratification Cohort at Week 8 (Negative Change Indicates Symptom Improvement)

InterventionalRandomizedquadruple589 enrolledStarted 2021-01Completion 2025-0450 sites · Canada, United StatesBiohaven Pharmaceuticals, Inc.

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

NCT03970447·Phase 2/Phase 3
Recruiting

Primary endpoint: Overall Survival (OS)

InterventionalRandomizedopen2,250 targetStarted 2019-07Completion 2030-0650 sites · Australia, Canada, United StatesGlobal Coalition for Adaptive Research

A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia.

NCT03701399·Phase 3·WST
Active, not recruiting

Primary endpoint: Randomization Phase: Change From Baseline in the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) Total Score at Week 48 in SCA Participants

InterventionalRandomizedquadruple299 targetStarted 2019-03Completion 2026-0823 sites · China, United StatesBiohaven Pharmaceuticals, Inc.